Clinical Trials Directory

Trials / Conditions / PARP Inhibitor

PARP Inhibitor

9 registered clinical trials studyying PARP Inhibitor — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingAn Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tol
NCT07359066
Shanghai SciBrunch Therapeutics Co., Ltd.Phase 1 / Phase 2
Active Not RecruitingThe HER Project: HRD in EGFR-mutated NSCLC
NCT07303218
IRCCS San Raffaele—
RecruitingREVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT06710548
Dana-Farber Cancer InstituteN/A
Not Yet RecruitingPARPi and Ovarian Cancer Survival
NCT06838429
Shanghai Gynecologic Oncology Group—
RecruitingSafety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
NCT06197581
Cancer Institute and Hospital, Chinese Academy of Medical SciencesN/A
RecruitingVismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Ca
NCT05538091
Ronald BuckanovichPhase 2
UnknownHomologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091
Xiaoxiang Chen—
UnknownThe Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
NCT04582552
Xiaoxiang Chen—
Active Not RecruitingPhase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Glioma
NCT03212742
Centre Francois BaclessePhase 1 / Phase 2